Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study

Open access
Pan, Pei-Yin, Lee, Meei-Shyuan, Lo, Miao-Chi, Yang, En-Lin, Yeh, Chin-Bin · 2014 · BMC Psychiatry

Abstract

BACKGROUND: Bipolar disorder is a highly recurrent disease and has great impact on the function of patients. Depressive symptoms consist of more than 50% of life time during the illness and may lead to self harm or suicidal behaviors. Little is known about the antidepressant effects of olanzapine, an atypical antipsychotic, as monotherapy despite its indication for preventing manic episodes. In contrast, lamotrigine, a mood stabilizer, has been proven to be effective in preventing depression in patients with bipolar disorder. However, no studies have compared the efficacy between lamotrigine and olanzapine in the maintenance treatment of bipolar disorder. This enriched naturalistic study was implemented to assess the effectiveness of olanzapine and lamotrigine as monotherapy in the prevention of recurrence of bipolar disorder. METHODS: Patients with bipolar disorder in a euthymic state (Young's Mania Rating Scale (YMRS) score <12, and 21-item Hamilton Depression Rating Scale (HAM-D) score <7) for at least two months, having already received either olanzapine or lamotrigine as the maintenance treatment were recruited. The patients maintained with olanzapine (n = 22) were applied to olanzapine group whereas those maintained with lamotrigine (n = 29) were applied to lamotrigine group. They were followed up for 12 months. Differences in the efficacy between olanzapine and lamotrigine in recurrence prevention were analyzed. The Kaplan-Meier method was used to generate time-to-recurrence curves, and differences between the two groups were compared using the log-rank test. RESULTS: Olanzapine had a significantly lower recurrence rate of depressive episodes than lamotrigine (20.0% vs. 57.7%, χ2 = 6.62, p = .010). However, olanzapine and lamotrigine had similar mania (15.0% vs. 0%, χ2 = 4.17, p = .075, Fisher's exact test) and any mood episode (35.0% vs. 57.7%, χ2 = 2.33, p = .127) recurrence rates. Olanzapine was significantly superior to lamotrigine in the time to recurrence of depressive episodes (χ2 = 4.55, df = 1, p = .033), but there was no difference in the time to recurrence of any mood episode (χ2 = 1.68, df = 1, p = .195). CONCLUSIONS: This prospective naturalistic study suggests that olanzapine is more effective than lamotrigine in the prevention of depressive episodes in patients with bipolar disorder. Future large-scale randomized studies are warranted to validate our results. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT01864551.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-244x-14-145

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition during the study.
Figure 1 Patient disposition during the study.CC BY · PubMed Central
Figure 2 Time to recurrence into depressive episode: Kaplan-Meier survival curves. The olanzapine group had a significantly longer time to recurrence into depressive episode than the lamotrigine group (χ2 = 4.55, df = 1, p = .033, log-rank test).
Figure 2 Time to recurrence into depressive episode: Kaplan-Meier survival curves. The olanzapine group had a significantly longer time to recurrence into depressive episode than the lamotrigine group (χ2 = 4.55, df = 1, p = .033, log-rank test).CC BY · PubMed Central
Figure 3 Time to recurrence into any mood episode: Kaplan-Meier survival curves. The olanzapine group did not differ from the lamotrigine group in time to recurrence to any mood episode (χ2 = 1.68, df = 1, p = .195, log-rank test).
Figure 3 Time to recurrence into any mood episode: Kaplan-Meier survival curves. The olanzapine group did not differ from the lamotrigine group in time to recurrence to any mood episode (χ2 = 1.68, df = 1, p = .195, log-rank test).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 9

Metadata

Authors
Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B.
Affiliations
  • Tri-Service General Hospital (TW)
  • National Defense Medical Center (TW)
Corresponding author
Yeh, Chin-Bin
Venue
BMC Psychiatry
Published
2014-05-19
Volume
14
Issue
1
Pages
145-145
ISSN
1471-244X (ISSN-L)
OpenAlex
W2072748137
Cited by
9
References
55
Citations by year
2022: 2 · 2021: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2015: 2
FWCI
0.76
Type
journal article
Language
en
Open access
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Tri-Service General Hospital
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
bipolar depression, olanzapine, lamotrigine, recurrence prevention, antidepressant monotherapy, atypical antipsychotics, mood stabilizers, time to recurrence, euthymic bipolar patients, treatment efficacy comparison, suicide risk, suicidal behavior, self-harm
MeSH terms
Olanzapine, Lamotrigine, Adult, Antidepressive Agents, Benzodiazepines, Bipolar Disorder, Depressive Disorder, Female, Humans, Male, Middle Aged, Prospective Studies, Antipsychotic Agents, Triazines, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. https://app.cochat.ai/papers/10.1186/1471-244x-14-145
The paper
Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B. (2014). Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.